Literature DB >> 19779766

Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems.

Shinsaku Imashuku1, Naoko Kinugawa2, Akinobu Matsuzaki3, Toshiyuki Kitoh4, Kentaro Ohki5, Yoko Shioda6, Yukiko Tsunematsu6, Toshihiko Imamura7, Akira Morimoto8.   

Abstract

Langerhans cell histiocytosis (LCH) can be a single system or multi-system disease. Both disease types can be associated with multi-focal bone lesions, but their bone involvement patterns have not been compared systematically. Of the new pediatric LCH cases enrolled into the JLSG-02 study during 2002-2007, 67 cases of single system multifocal bone (SMFB) LCH and 97 cases of multi-system bone (MSB) LCH were analyzed to determine if the bone involvement patterns differ in these two types, and whether these differences correlate with outcome. Statistical analysis was performed with Mann-Whitney U test, Fisher's exact test, and other measures. Onset ages were higher for SMFB (P < 0.001), but the two types did not differ in the number of bone lesions per patient. The skull was most frequently affected in both types, followed by the spine. Lesions in the temporal bone (P = 0.002), ear-petrous bone (P < 0.001), orbita (P = 0.003), and zygomatic bone (P = 0.016) were significantly more common in MSB. The two types did not differ in response to treatment, but MSB was associated with a significantly higher incidence of diabetes insipidus (DI) (P < 0.001). Novel measures are required in preventing the development of DI in MSB-type LCH patients with "risk" bone lesions.

Entities:  

Mesh:

Year:  2009        PMID: 19779766     DOI: 10.1007/s12185-009-0420-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  [Treatment concepts in osseous manifestations of Langerhans cell histiocytosis].

Authors:  W Nebelung; M Röpke; U Kluba; V Aumann; K Radig; U Mittler
Journal:  Z Orthop Ihre Grenzgeb       Date:  1999 May-Jun

2.  Risk factors for diabetes insipidus in langerhans cell histiocytosis.

Authors:  N Grois; U Pötschger; H Prosch; M Minkov; M Arico; J Braier; J-I Henter; G Janka-Schaub; S Ladisch; J Ritter; M Steiner; E Unger; H Gadner
Journal:  Pediatr Blood Cancer       Date:  2006-02       Impact factor: 3.167

Review 3.  Eosinophilic granuloma of bone.

Authors:  J M Slater; O J Swarm
Journal:  Med Pediatr Oncol       Date:  1980

4.  Predictors of outcome in children with Langerhans cell histiocytosis.

Authors:  Rima F Jubran; Araz Marachelian; Frederick Dorey; Marcio Malogolowkin
Journal:  Pediatr Blood Cancer       Date:  2005-07       Impact factor: 3.167

Review 5.  Langerhans cell histiocytosis of bone.

Authors:  M A Stull; M J Kransdorf; K O Devaney
Journal:  Radiographics       Date:  1992-07       Impact factor: 5.333

6.  Langerhans'-cell histiocytosis in adults.

Authors:  I Baumgartner; A von Hochstetter; B Baumert; U Luetolf; F Follath
Journal:  Med Pediatr Oncol       Date:  1997-01

7.  Craniospinal Langerhans cell histiocytosis in children: 30 years' experience at a single institution.

Authors:  Laurence Davidson; J Gordon McComb; Ira Bowen; Mark D Krieger
Journal:  J Neurosurg Pediatr       Date:  2008-03       Impact factor: 2.375

8.  Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis.

Authors:  Nicole Grois; Daniela Prayer; Helmut Prosch; Milen Minkov; Ulrike Pötschger; Helmut Gadner
Journal:  Pediatr Blood Cancer       Date:  2004-07       Impact factor: 3.167

9.  Langerhans cell histiocytosis of bone in children and adolescents.

Authors:  Ismat Ghanem; Vernon T Tolo; Pyllis D'Ambra; Marcio H Malogalowkin
Journal:  J Pediatr Orthop       Date:  2003 Jan-Feb       Impact factor: 2.324

10.  Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

Authors:  Riccardo Haupt; Vasanta Nanduri; Maria Grazia Calevo; Cecilia Bernstrand; Jorge L Braier; Valerie Broadbent; Guadalupe Rey; Kenneth L McClain; Gritta Janka-Schaub; R Maarten Egeler
Journal:  Pediatr Blood Cancer       Date:  2004-05       Impact factor: 3.167

View more
  5 in total

1.  Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan.

Authors:  Yoko Shioda; Souichi Adachi; Shinsaku Imashuku; Kazuko Kudo; Toshihiko Imamura; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

2.  Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.

Authors:  Toshihiko Imamura; Takashi Sato; Yoko Shiota; Hirokazu Kanegane; Kazuko Kudo; Shinichirou Nakagawa; Hisaya Nakadate; Hisamichi Tauchi; Junji Kamizono; Akira Morimoto
Journal:  Int J Hematol       Date:  2010-04-02       Impact factor: 2.490

Review 3.  Langerhans cell histiocytosis of the orbit: five clinicopathologic cases and review of the literature.

Authors:  Martina C Herwig; Ted Wojno; Qing Zhang; Hans E Grossniklaus
Journal:  Surv Ophthalmol       Date:  2012-12-13       Impact factor: 6.048

4.  Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy.

Authors:  Mariko Minami; Takahiro Shima; Koji Kato; Hidetaka Yamamoto; Kenji Tsuchihashi; Seido Oku; Tomonori Shimokawa; Taro Tochigi; Goichi Yoshimoto; Kenjiro Kamezaki; Katsuto Takenaka; Hiromi Iwasaki; Yoshinao Oda; Toshihiro Miyamoto; Koichi Akashi
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

5.  A rare case of solitary unifocal Langerhans cell histiocytosis with orbital extension: Diagnostic dilemma.

Authors:  Maftuhim Addenan; Choo May May; Teoh Kean Hooi; Fazliana Ismail; Tengku Ain Kamalden
Journal:  Oman J Ophthalmol       Date:  2018 Sep-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.